LXEO Stock — Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock (LXEO)

Updated October 16, 2026.

LXEO is a Stock. Total return is -76.0% over the past 3 years, 159.7 points behind SPY at 83.7%.

Lexeo Therapeutics is a clinical-stage genetic medicine company developing gene therapy candidates to treat hereditary and acquired cardiac and neurological diseases, including friedreich ataxia cardiomyopathy, arrhythmogenic cardiomyopathy, and Alzheimer's disease. The company does not currently distribute to shareholders. This security appeals to investors seeking exposure to early-stage biotechnology development with high risk and potential for long-term capital appreciation rather than current income.

LXEO performance versus SPY

Price and return data through 2026-10-16.

Total return is -76.0% over the past 3 years, 159.7 points behind SPY at 83.7%. Over the past year its total return — price change plus distributions reinvested — is -69.9%. Its deepest 1-year drawdown was 75.3%.

LXEO key facts

Asset type

Stock

Asset class

Equity

Inception date

11/02/2023

Distribution frequency

None

Last close

$2.64 (as of 2026-10-16)

Market cap

$216,712,727

Average volume

2506681.0

Beta

1.64

Payout ratio

0.0%

Forward P/E

6.3532

EPS

$-1.02

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

LXEO risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 75.3%.

Who may consider LXEO — and who may not

It is a weaker fit for investors who need monthly cash flow (LXEO does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on LXEO

• All tickers starting with L

Tagged: Healthcare.

Frequently asked questions